Preimplantation genetic testing and disorders of placental implantation: a systematic review and meta-analysis.

IF 3.2 3区医学 Q2 GENETICS & HEREDITY

Journal of Assisted Reproduction and Genetics Pub Date : 2025-03-13 DOI:10.1007/s10815-025-03441-5

Isaac J Chamani, Lauren L Taylor, Hailie Ciomperlik, Timothy Dunn, Anna C Reynolds, Beatriz Varman, Karin A Fox, Laura Detti

{"title":"Preimplantation genetic testing and disorders of placental implantation: a systematic review and meta-analysis.","authors":"Isaac J Chamani, Lauren L Taylor, Hailie Ciomperlik, Timothy Dunn, Anna C Reynolds, Beatriz Varman, Karin A Fox, Laura Detti","doi":"10.1007/s10815-025-03441-5","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate whether embryo biopsy for preimplantation genetic testing (PGT) during in vitro fertilization (IVF) increases the risk of disorders related to abnormal placental implantation.Methods: A systematic search of Medline, Embase, and Web of Science was performed on February 17, 2023, and identified studies on placental implantation anomalies following PGT in IVF patients. The primary outcome was placenta accreta spectrum (PAS), while secondary outcomes included placental abruption, placenta previa, preterm premature rupture of membranes (PPROM), and hypertensive pregnancy disorders. Only peer-reviewed randomized controlled trials, cohort, case-control, and cross-sectional studies in English were considered. Two reviewers independently screened citations, extracted data, and assessed study quality. Data analysis was performed using RevMan 5.4.Results: Of 282 citations retrieved by our search, 8 studies met inclusion criteria. There was no statistically significant difference in PAS risk between groups (aggregated OR 0.78, 95% CI 0.22-2.76, P = 0.70). Amongst secondary outcomes, mean BMI was lower in PGT patients (mean difference - 0.57, 95% CI - 0.98 to - 0.17, P = 0.005), and PPROM rates were higher (OR 1.29, 95% CI 1.04-1.60, P = 0.02). Other secondary outcomes showed no significant differences.Conclusion: Embryo biopsy for PGT in IVF was not associated with an increased risk of PAS. However, PGT was more commonly performed in patients with lower BMI, and an elevated risk of PPROM was observed, primarily driven by a single study. Further investigation is needed to clarify this finding and its implications.","PeriodicalId":15246,"journal":{"name":"Journal of Assisted Reproduction and Genetics","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Assisted Reproduction and Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10815-025-03441-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate whether embryo biopsy for preimplantation genetic testing (PGT) during in vitro fertilization (IVF) increases the risk of disorders related to abnormal placental implantation.

Methods: A systematic search of Medline, Embase, and Web of Science was performed on February 17, 2023, and identified studies on placental implantation anomalies following PGT in IVF patients. The primary outcome was placenta accreta spectrum (PAS), while secondary outcomes included placental abruption, placenta previa, preterm premature rupture of membranes (PPROM), and hypertensive pregnancy disorders. Only peer-reviewed randomized controlled trials, cohort, case-control, and cross-sectional studies in English were considered. Two reviewers independently screened citations, extracted data, and assessed study quality. Data analysis was performed using RevMan 5.4.

Results: Of 282 citations retrieved by our search, 8 studies met inclusion criteria. There was no statistically significant difference in PAS risk between groups (aggregated OR 0.78, 95% CI 0.22-2.76, P = 0.70). Amongst secondary outcomes, mean BMI was lower in PGT patients (mean difference - 0.57, 95% CI - 0.98 to - 0.17, P = 0.005), and PPROM rates were higher (OR 1.29, 95% CI 1.04-1.60, P = 0.02). Other secondary outcomes showed no significant differences.

Conclusion: Embryo biopsy for PGT in IVF was not associated with an increased risk of PAS. However, PGT was more commonly performed in patients with lower BMI, and an elevated risk of PPROM was observed, primarily driven by a single study. Further investigation is needed to clarify this finding and its implications.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Assisted Reproduction and Genetics 医学-妇产科学

CiteScore

5.70

自引率

9.70%

发文量

286

审稿时长

1 months

期刊介绍： The Journal of Assisted Reproduction and Genetics publishes cellular, molecular, genetic, and epigenetic discoveries advancing our understanding of the biology and underlying mechanisms from gametogenesis to offspring health. Special emphasis is placed on the practice and evolution of assisted reproduction technologies (ARTs) with reference to the diagnosis and management of diseases affecting fertility. Our goal is to educate our readership in the translation of basic and clinical discoveries made from human or relevant animal models to the safe and efficacious practice of human ARTs. The scientific rigor and ethical standards embraced by the JARG editorial team ensures a broad international base of expertise guiding the marriage of contemporary clinical research paradigms with basic science discovery. JARG publishes original papers, minireviews, case reports, and opinion pieces often combined into special topic issues that will educate clinicians and scientists with interests in the mechanisms of human development that bear on the treatment of infertility and emerging innovations in human ARTs. The guiding principles of male and female reproductive health impacting pre- and post-conceptional viability and developmental potential are emphasized within the purview of human reproductive health in current and future generations of our species. The journal is published in cooperation with the American Society for Reproductive Medicine, an organization of more than 8,000 physicians, researchers, nurses, technicians and other professionals dedicated to advancing knowledge and expertise in reproductive biology.